Hospira is voluntarily recalling three lots of the injectable opioid medication Hydromorphone HCl because the glass vials may be broken or cracked, the Food and Drug Administration announced yesterday. Hospira has notified hospitals and others with an existing inventory of the lots subject to this recall that they should stop use and distribution of the remaining units and quarantine them immediately. See the FDA announcement for more information, including the lot numbers. Health care professionals are encouraged to report any related problems or events to the FDA's MedWatch Program. Last week, the AHA and others asked the Drug Enforcement Administration to temporarily adjust the aggregate production quotas for certain injectable opioid medications in short supply to allow other manufacturers to supply product until the shortages resolve.
 

Headline
Elizabeth Mort, M.D., vice president and chief medical officer at Joint Commission, breaks down the five critical priorities boards must focus on — …
Blog
High-quality maternal care is essential to protecting the health of both mom and baby during birth.Sutter Health is taking a proactive, systemwide approach to…
Headline
USA Today published a column  by AHA Board Chair Marc Boom, M.D., president and CEO of Houston Methodist, highlighting how hospitals and health systems…
Blog
h2, h3, h4 {color: #002855;} Postpartum hemorrhage (PPH) is one of the most common — and preventable — causes of maternal health in the United States. The…
Chairperson's File
Public
For decades, hospitals and health systems have used innovation to improve patient care and outcomes. We have seen dramatic improvements and know we can never…
Headline
March 8-14 marks Patient Safety Awareness Week. The AHA has several resources including podcasts, videos and reports that show how AHA members are advancing…